home / stock / ifrx / ifrx articles

IFRX Articles, InflaRx N.V.

Stock Information
Company Name: InflaRx N.V.
Stock Symbol: IFRX
Market: NASDAQ
Website: inflarx.de
Menu
IFRX IFRX Quote IFRX Short IFRX News IFRX Articles IFRX Message Board
Get IFRX Alerts

News, Short Squeeze, Breakout and More Instantly...
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators | Benzinga

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutic...
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024 | Benzinga

JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeut...

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event | Benzinga

JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biotechnology company pioneering anti-inflammatory therapeutics ...

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans | Benzinga

InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobe...
InflaRx Appoints Jan Medina as Head of Investor Relations | Benzinga

JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeuti...

Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket | Benzinga

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explor...

Why DigitalOcean Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket | Benzinga

Gainers Altamira Therapeutics Ltd (NASDAQ: CYTO) shares surged 54.1% to $0.25 in pre-market trading after gaining 5% on Thursday. Eiger BioPharmace...
InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA) | Benzinga

MAA for vilobelimab was submitted in July MAA has been validated by EMA and is now under review Regulatory submission based on pivotal data from ...

Next 10